Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring
Source: Streetwise Reports  (11/15/19)
Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. More >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher
Source: Streetwise Reports  (11/14/19)
Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. More >

Biopharma Presents Data on Alcoholic Hepatitis Therapeutic at Liver Meeting
Source: Streetwise Reports  (11/13/19)
The company intends to follow up in 2020 with a Phase 2b clinical trial. More >

FDA Approval of Peanut Allergy Treatment Expected Next Year
Source: Streetwise Reports  (11/13/19)
The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. More >

Clinical Trial Results for Alcoholic Hepatitis Drug Delivered in Webcast
Source: Streetwise Reports  (11/13/19)
The online presentation coincides with The Liver Meeting 2019, at which data also are shared. More >

Seachange in Mexico on Cannabis Could Benefit This Small Cap
Source: Clive Maund for Streetwise Reports  (11/13/19)
Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. More >

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results
Source: Streetwise Reports  (11/8/19)
Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. More >

Could There Finally Be an Effective Treatment for Alzheimer's Disease?
Source: Streetwise Reports  (11/6/19)
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. More >

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance
Source: Streetwise Reports  (11/6/19)
Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. More >

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia
Source: Streetwise Reports  (11/4/19)
Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. More >

BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership
Source: Streetwise Reports  (11/1/19)
Shares of BeiGene Ltd. traded 35% higher today to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. More >

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data
Source: Streetwise Reports  (10/28/19)
Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. More >

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses'
Source: Streetwise Reports  (10/23/19)
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. More >

Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases
Source: Streetwise Reports  (10/23/19)
These therapeutic candidates add to those already in the firm's pipeline. More >

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings
Source: Streetwise Reports  (10/22/19)
Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today. More >

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis
Source: Streetwise Reports  (10/21/19)
The details of this study and a second one are outlined in a ROTH Capital Partners report. More >

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher
Source: Streetwise Reports  (10/18/19)
Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. More >

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data
Source: Streetwise Reports  (10/17/19)
Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. More >

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer
Source: Streetwise Reports  (10/16/19)
Shares of Achillion Pharmaceuticals are trading much higher today after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. More >

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho
Source: Streetwise Reports  (10/16/19)
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. More >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results
Source: Streetwise Reports  (10/15/19)
Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. More >

Technical Analyst Expects Health Technologies Firm to Break Higher
Source: Clive Maund for Streetwise Reports  (10/14/19)
Technical analyst Clive Maund outlines the reasons this stock might break higher. More >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million
Source: Streetwise Reports  (10/14/19)
Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. More >

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights
Source: Streetwise Reports  (10/11/19)
Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. More >

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid
Source: Streetwise Reports  (10/10/19)
Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. More >